Drug developpment Drug developpment
logo
Select your search
Contact us
You are here : Biosafety

Biosafety: a Fundamental Issue

Biosafety Bertin Pharma

The biosafety of drug candidates or any other xenobiotic or product used by humans is a fundamental issue that requires the application of guidelines and the implementation of standardized experimental tests.

Bertin Pharma, throughout its years of expertise, has always focused on the efficacy as much as on the safety of products assessed in its laboratories.

Safety Pharmacology including Safety ImmunoPharmacology & the Viral & Prions risk are historical topics for Bertin Pharma biologics (peptides/proteins, gene therapy, cell therapy, etc.) and/or blood derivative products but remain essential subjects and two of its core activities.

Now, impurities and Host Cell Contaminants such as proteins (HCP) and nucleic acids are important issues, also evaluated by Bertin Pharma.

top

Bertin Pharma - Drug developpment

Follow Us

Linkedin Youtube Twitter Google+

Contact us

Any project? Any challenge? We are in!
+33 (0) 139 306 260
Any questions? Contact us

Headquarters:
Parc d’Activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux - France
View our other locations

Newsletter

Do you want to be kept updated with Bertin Pharma's latest news?

Manage my subscriptions